Unjha Formulations Falls 3.16% Amid Valuation Shift and Mixed Q2 Results
2026-11-07 15:06:09Key Events This Week Nov 2: Valuation shifts to fair amid sector comparisons Nov 3: Continued price decline despite Sensex rally Nov 4: Strong intraday recovery with volume surge Nov 5: Further gains on positive market momentum Nov 6: Q2 FY27 results show profit rebound but stock falls Week OpenRs.28.45 ...
Read More
Unjha Formulations Ltd: Valuation Shift Enhances Price Attractiveness Amid Sector Challenges
2026-10-27 08:01:07Unjha Formulations Ltd has seen a notable shift in its valuation parameters, moving from fair to attractive territory despite recent market headwinds. This change reflects a recalibration of investor sentiment amid a challenging Pharmaceuticals & Biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now offering a more compelling entry point relative to peers and historical averages.
Read More
Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 36.38
2026-09-10 11:41:07Surging past its previous peak, Unjha Formulations Ltd reached a fresh 52-week high of Rs 36.38 on 10 Sep 2026, propelled by a sustained rally that has delivered a 46.16% gain over the past ten trading sessions.
Read More
Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 35.39
2026-09-09 10:43:54After a sustained rally over the past nine sessions, Unjha Formulations Ltd surged to a fresh 52-week high of Rs 35.39 on 9 Sep 2026, marking a 42.19% gain since its recent low. This price milestone is underpinned by a confluence of bullish technical indicators and robust price momentum, setting the stock apart in a market environment where the broader Sensex has been under pressure.
Read More
Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 33.4
2026-09-08 10:36:51With a decisive surge to Rs 33.4 on 8 Sep 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a 91% rally from its low of Rs 17.52 over the past year. This milestone is underscored by a strong alignment of technical indicators and sustained price momentum, even as the broader market struggles to hold ground.
Read MoreUnjha Formulations Gains 17.30%: 4 Key Factors Driving the Surge
2026-09-05 15:07:24Key Events This Week 31 Aug: Upgraded to Hold on Technical and Valuation Improvements 1 Sep: Downgraded to Sell amid Mixed Technicals and Fair Valuation 1 Sep: Valuation Shift Signals Caution Amid Strong Returns 4 Sep: Hits New 52-Week High at Rs.30.5 Week OpenRs.26.12 Week CloseRs.30.64<...
Read More
Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 30.5
2026-09-04 10:44:00Surging to a fresh 52-week high of Rs 30.5 on 4 Sep 2026, Unjha Formulations Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market over the past week and beyond.
Read More
Unjha Formulations Ltd: Valuation Shift Signals Caution Amid Strong Returns
2026-09-01 08:00:41Unjha Formulations Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade amid evolving market dynamics. This change reflects a recalibration of investor sentiment, driven by adjustments in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, when compared to both historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.
Read More
Unjha Formulations Ltd Upgraded to Hold on Technical and Valuation Improvements
2026-08-31 08:03:21Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The upgrade, effective from 28 August 2026, is driven primarily by bullish technical trends, attractive valuation relative to peers, and a stable financial outlook, positioning the micro-cap pharmaceutical company for cautious optimism among investors.
Read MorePublish Audited Financial Results For The Quarter And Half Year Ended As On 30/09/2026
06-Nov-2026 | Source : BSEApproval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2026 And Out Come Of Board Meeting Held On 5Th November 2026.
05-Nov-2026 | Source : BSEREGULATION 33 OF SEBI (LODR) REGU 2015
Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2026 And Out Come Of Board Meeting Held On 5Th November 2026.
05-Nov-2026 | Source : BSEREGULATION 33 OF SEBI LODR REGU 2015
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available